• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.纤溶酶原激活物抑制剂-1 与结直肠肿瘤的相关性。
Gut Liver. 2013 Sep;7(5):519-23. doi: 10.5009/gnl.2013.7.5.519. Epub 2013 Jun 11.
2
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.组织蛋白酶B、组织蛋白酶L、尿激酶型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1、癌胚抗原和CA 19-9在结直肠癌中的肿瘤标志物效用及预后相关性
BMC Cancer. 2008 Jul 10;8:194. doi: 10.1186/1471-2407-8-194.
3
Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection.微创结直肠癌切除术后纤溶酶原激活物抑制剂-1的血浆水平持续升高。
Mol Clin Oncol. 2022 Feb;16(2):28. doi: 10.3892/mco.2021.2461. Epub 2021 Dec 8.
4
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.纤溶酶原激活的改变与结直肠腺瘤中上皮细胞发育异常分级相关。
Br J Cancer. 1998;77(2):297-304. doi: 10.1038/bjc.1998.46.
5
Plasminogen activator inhibitor-1 is associated with the metabolism and development of advanced colonic polyps.纤溶酶原激活物抑制剂-1 与高级结肠息肉的代谢和发展有关。
Transl Res. 2018 Oct;200:43-53. doi: 10.1016/j.trsl.2018.05.010. Epub 2018 Jun 6.
6
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.更大且侵袭性更强的结肠直肠癌含有更多的1型纤溶酶原激活物抑制剂,其与尿激酶受体的相对比例与肿瘤大小密切相关。
Cancer. 1999 Dec 15;86(12):2602-11. doi: 10.1002/(sici)1097-0142(19991215)86:12<2602::aid-cncr4>3.0.co;2-s.
7
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.结直肠癌患者术前血浆纤溶酶原激活物抑制剂-1水平与血清C反应蛋白水平。RANX05结直肠癌研究组。
Ann Surg Oncol. 2000 Sep;7(8):617-23. doi: 10.1007/BF02725342.
8
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1以及组织型纤溶酶原激活剂/纤溶酶原激活剂抑制剂-1复合物作为首次中风发生的危险因素。
Stroke. 2000 Jan;31(1):26-32. doi: 10.1161/01.str.31.1.26.
9
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.在斯德哥尔摩心脏流行病学项目(SHEEP)研究中,血浆组织型纤溶酶原激活剂/纤溶酶原激活剂抑制剂-1复合物水平和血管性血友病因子是复发性心肌梗死的重要风险标志物。
Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. doi: 10.1161/01.atv.20.8.2019.
10
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.肝细胞癌的侵袭和转移与尿激酶型纤溶酶原激活物、其受体及抑制剂的关系
J Cancer Res Clin Oncol. 2000 Nov;126(11):641-6. doi: 10.1007/s004320000146.

引用本文的文献

1
Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer.癌症相关脂肪细胞在结直肠癌中的多方面作用
Biomedicines. 2023 Aug 28;11(9):2401. doi: 10.3390/biomedicines11092401.
2
A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer.一种基于丝氨酸蛋白酶抑制剂E1的免疫基因特征可预测胃癌的预后和免疫治疗反应。
Pharmaceuticals (Basel). 2022 Nov 14;15(11):1401. doi: 10.3390/ph15111401.
3
PAI-1 expression in intratumoral inflammatory infiltrate contributes to lymph node metastasis in oral cancer: A cross-sectional study.肿瘤内炎性浸润中PAI-1的表达促进口腔癌淋巴结转移:一项横断面研究。
Ann Med Surg (Lond). 2021 Apr 15;65:102303. doi: 10.1016/j.amsu.2021.102303. eCollection 2021 May.
4
Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights.肥胖与结直肠癌的关联:流行病学及机制洞察
Cancers (Basel). 2020 May 29;12(6):1408. doi: 10.3390/cancers12061408.
5
Tumor Budding, uPA, and PAI-1 in Colorectal Cancer: Update of a Prospective Study.结直肠癌中的肿瘤芽、尿激酶型纤溶酶原激活物及纤溶酶原激活物抑制剂-1:一项前瞻性研究的更新
Gastroenterol Res Pract. 2017;2017:6504960. doi: 10.1155/2017/6504960. Epub 2017 Feb 12.
6
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.Bmi-1和PAI-1在食管鳞状细胞癌中的表达。
World J Gastroenterol. 2014 May 14;20(18):5533-9. doi: 10.3748/wjg.v20.i18.5533.

本文引用的文献

1
Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population.中心型肥胖和代谢综合征的致动脉粥样硬化性血脂异常与中国人群结直肠腺瘤风险增加相关。
BMC Gastroenterol. 2010 May 27;10:51. doi: 10.1186/1471-230X-10-51.
2
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.尿激酶型纤溶酶原激活剂(uPA)和纤溶酶原激活物抑制剂-1(PAI-1)对结肠癌和直肠癌的预后影响差异
Tumour Biol. 2009;30(4):210-20. doi: 10.1159/000239796. Epub 2009 Sep 21.
3
The plasminogen activator system and cancer.纤溶酶原激活物系统与癌症。
Pathophysiol Haemost Thromb. 2008;36(3-4):184-94. doi: 10.1159/000175156. Epub 2009 Jan 27.
4
The plasminogen activator inhibitor "paradox" in cancer.癌症中的纤溶酶原激活物抑制剂“悖论”
Immunol Lett. 2008 Jun 30;118(2):116-24. doi: 10.1016/j.imlet.2008.03.017. Epub 2008 May 2.
5
Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.纤溶酶原激活物抑制剂-1(Pai-1)阻滞剂可抑制Min小鼠肠道息肉的形成。
Carcinogenesis. 2008 Apr;29(4):824-9. doi: 10.1093/carcin/bgn028. Epub 2008 Feb 6.
6
PAI-1 - a potential therapeutic target in cancer.纤溶酶原激活物抑制剂-1——癌症的一个潜在治疗靶点。
Curr Drug Targets. 2007 Sep;8(9):1030-41. doi: 10.2174/138945007781662346.
7
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.尿激酶纤溶酶原激活系统基因多态性与结直肠癌的关系
Ann Oncol. 2007 Dec;18(12):1990-4. doi: 10.1093/annonc/mdm361. Epub 2007 Sep 5.
8
Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men.高甘油三酯血症与日本男性结直肠管状腺瘤的发生呈正相关。
World J Gastroenterol. 2006 Feb 28;12(8):1261-4. doi: 10.3748/wjg.v12.i8.1261.
9
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.尿激酶纤溶酶原激活物系统:癌症患者个体化管理中肿瘤标志物的丰富来源。
Clin Biochem. 2004 Jul;37(7):541-8. doi: 10.1016/j.clinbiochem.2004.05.013.
10
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.纤溶酶原激活物抑制剂-1在肿瘤生长、血管生成和血管重塑中的作用
Curr Pharm Des. 2003;9(19):1545-64. doi: 10.2174/1381612033454621.

纤溶酶原激活物抑制剂-1 与结直肠肿瘤的相关性。

Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.

机构信息

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2013 Sep;7(5):519-23. doi: 10.5009/gnl.2013.7.5.519. Epub 2013 Jun 11.

DOI:10.5009/gnl.2013.7.5.519
PMID:24073308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3782665/
Abstract

BACKGROUND/AIMS: Plasminogen activator inhibitor-1 (PAI-1) is important for tumor growth, Invasion, and metastasis. In this study, we investigated the relationship between plasma levels of PAI-1 and colorectal adenomas.

METHODS

We reviewed the medical records of 3,136 subjects who underwent colonoscopy as a screening exam. The subjects were classified into a case group with adenomas (n=990) and a control group (n=2,146). Plasma PAI-1 levels were categorized into three groups based on tertile.

RESULTS

The plasma levels of PAI-1 were significantly higher in adenoma cases than in controls (p=0.023). The prevalence of colorectal adenomas increased significantly with increasing levels of PAI-1 (p=0.038). In the adenoma group, advanced pathologic features, size, and number of adenomas did not differ among the three groups based on tertiles for plasma PAI-1 levels. Using multivariate analysis, we found that plasma level of PAI-1 was not associated with the risk of colorectal adenomas (p=0.675). Adjusted odds ratios for colorectal adenomas according to increasing plasma levels of PAI-1 were 0.980 (95% confidence interval [CI], 0.768 to 1.251) for the second-highest plasma level and 1.091 (95% CI, 0.898 to 1.326) for the highest level, compared with the lowest levels.

CONCLUSIONS

These results suggest that elevated plasma PAI-1 levels are not associated with the risk of colorectal neoplasms.

摘要

背景/目的:纤溶酶原激活物抑制剂-1(PAI-1)对肿瘤的生长、侵袭和转移很重要。本研究旨在探讨血浆 PAI-1 水平与结直肠腺瘤之间的关系。

方法

我们回顾性分析了 3136 例接受结肠镜筛查的患者的病历资料。根据有无腺瘤将患者分为病例组(n=990)和对照组(n=2146)。根据三分类法将血浆 PAI-1 水平分为三组。

结果

病例组患者的血浆 PAI-1 水平明显高于对照组(p=0.023)。随着 PAI-1 水平的升高,结直肠腺瘤的患病率显著增加(p=0.038)。在腺瘤组中,根据血浆 PAI-1 水平三分位,高级别病理特征、腺瘤大小和数量在三组之间无显著差异。多变量分析显示,血浆 PAI-1 水平与结直肠腺瘤风险无关(p=0.675)。根据血浆 PAI-1 水平升高,结直肠腺瘤的调整比值比分别为第二高血浆水平时的 0.980(95%置信区间,0.768 至 1.251)和最高水平时的 1.091(95%置信区间,0.898 至 1.326),与最低水平相比。

结论

这些结果表明,血浆 PAI-1 水平升高与结直肠肿瘤的风险无关。